RxDoctor Payments Data

Reena Mehra, MD

Pulmonary Disease · Seattle, WANPI 1578583290

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $26,814 of the $36,061 with a category attached, or 74.4%. 10 manufacturers reported payments, led by Lilly USA, LLC at 35.6% of the total. Reporting peaked in 2019 at $16,592 and has fallen 91.1% since, to $1,481 in 2025. Among pulmonary disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,061in general payments, 2019–2025

Across 53 payments — averaging $680.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$13K
  • Merck$11K
  • ZOLL Respicardia, Inc.$5K
  • Eli Lilly$4K
  • Amgen$1K
  • Jazz Pharmaceuticals Inc.$561
  • plus $533 from 4 others
$175,601in research payments, 2019–2025

Across 37 payments — averaging $4745.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inspire Medical Systems, Inc.$175K
  • Kyowa Kirin, Inc.$1K

What the payments were for

  • Consulting fees$26,81474%
  • Speaking & faculty fees$2,5007%
  • Travel & lodging$4,68013%
  • Food & beverage$2,0676%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC20$12,854
Merck15$11,498
ZOLL Respicardia, Inc.4$5,301
Eli Lilly1$4,000
Amgen1$1,314
Jazz Pharmaceuticals Inc.7$561
Intuitive Surgical2$238
Boston Scientific1$125
Body Vision Medical Inc.1$111
Visionair Solutions, LLC1$58

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,061 in reported general payments places this provider in the 95th percentile of 275 pulmonary disease providers in Washington.

See all pulmonary disease providers in Washington

Medicare billing

Part B allowed, 2024
$4,568
Medicare patients
56
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →